ADTX — Aditxt Share Price
0.000.00%
Last trade - 00:00- $0.11m
- -$2.89m
- $0.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.02 | ||
| Price to Tang. Book | 0.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 33.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -457.4% | ||
| Return on Equity | -1411.72% | ||
| Operating Margin | -614207.81% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.11 | 0.93 | 0.65 | 0.13 | 0 | 1.26 | 1.32 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +39.9 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. The Company operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimune’s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. It is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.
Directors
- Amro Albanna CHM (51)
- Corinne Pankovcin PRE (54)
- Thomas Farley CFO (48)
- Rowena Albanna COO (55)
- Shahrokh Shabahang OTH (58)
- Jeffrey Runge LED
- Brian Brady IND (41)
- Namvar Kiaie IND (54)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- September 28th, 2017
- Public Since
- June 19th, 2020
- No. of Shareholders
- 174
- No. of Employees
- 26
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 904,468
- Address
- 737 N. Fifth Street, Suite 200, RICHMOND, 23219
- Web
- https://aditxt.com/
- Phone
- +1 3027449800
- Auditors
- dbbmckennon
Upcoming Events for ADTX
Q2 2026 Aditxt Inc Earnings Release
Aditxt Inc Annual Shareholders Meeting
Similar to ADTX
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Aditxt share price?
As of Today at 19:04 UTC, shares in Aditxt are trading at $0.12. This share price information is delayed by 15 minutes.
How has the Aditxt share price performed this year?
Shares in Aditxt last closed at $0.12 and the price had moved by -99.99% over the past 365 days. In terms of relative price strength the Aditxt share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Aditxt?
The overall consensus recommendation for Aditxt is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aditxt dividend yield?
Aditxt does not currently pay a dividend.
Does Aditxt pay a dividend?
Aditxt does not currently pay a dividend.
When does Aditxt next pay dividends?
Aditxt does not currently pay a dividend.
How do I buy Aditxt shares?
To buy shares in Aditxt you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aditxt?
As of the previous close price of $0.12, shares in Aditxt had a market capitalisation of $0.11m.
Where are Aditxt shares listed?
Here are the trading details for Aditxt:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ADTX
What kind of share is Aditxt?
Based on an overall assessment of its quality, value and momentum Aditxt is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aditxt share price forecast for 2026?
The analyst consensus target price for shares in Aditxt is $61.00. That is 51246.8% above the last closing price of $0.12.
Analysts covering Aditxt currently have a consensus Earnings Per Share (EPS) forecast of $243.60 for the next financial year.
Find out moreWhat is the trend in the Aditxt share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aditxt. Over the past six months, its share price has underperformed the S&P500 Index by -25.27%.
As of the last closing price of $0.12, shares in Aditxt were trading -99.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aditxt PE Ratio?
The Aditxt PE ratio based on its reported earnings over the past 12 months is 0. The shares last closed at $0.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aditxt?
Aditxt's management team is headed by:
- Amro Albanna - CHM
- Corinne Pankovcin - PRE
- Thomas Farley - CFO
- Rowena Albanna - COO
- Shahrokh Shabahang - OTH
- Jeffrey Runge - LED
- Brian Brady - IND
- Namvar Kiaie - IND